asset acquisition

Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.

A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.

Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.

The purchase provides Thermo Fisher with access to the $40 billion pharmaceutical contract development and manufacturing market.

Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.

The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.

CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal. 

Pages

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.